Jon P Stonehouse Biocryst Pharmaceuticals Inc (BCRX) insider trading activity

Jon P Stonehouse is President & CEO of BIOCRYST PHARMACEUTICALS INC. Currently has a direct ownership of 1.43 Million shares of BCRX, which is worth approximately $12.9 Million. The most recent transaction as insider was on Dec 20, 2024, when has been sold 20,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.43M

26.72% 3M change

30.54% 12M change

Total Value Held $12.9 Million

Jon P Stonehouse Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 20 2024	SELL Bona fide gift	-	20,000 Reduced 1.38%	1,429,109 Common Stock
Dec 19 2024	SELL Payment of exercise price or tax liability	$103,533 $7.39 p/Share	14,010 Reduced 0.96%	1,449,109 Common Stock
Dec 19 2024	BUY Grant, award, or other acquisition	-	362,100 Added 19.84%	1,463,119 Common Stock
Dec 14 2024	SELL Payment of exercise price or tax liability	$207,263 $7.53 p/Share	27,525 Reduced 2.44%	1,101,019 Common Stock
May 13 2024	BUY Open market or private purchase	$166,500 $5.55 p/Share	30,000 Added 2.59%	1,127,770 Common Stock
Jan 03 2024	SELL Bona fide gift	-	20,000 Reduced 1.79%	1,094,770 Common Stock
Dec 19 2023	SELL Payment of exercise price or tax liability	$85,238 $6.05 p/Share	14,089 Reduced 1.25%	1,114,770 Common Stock
Dec 14 2023	SELL Payment of exercise price or tax liability	$87,396 $6.43 p/Share	13,592 Reduced 1.19%	1,128,859 Common Stock
Dec 14 2023	BUY Grant, award, or other acquisition	-	127,500 Added 10.04%	1,142,451 Common Stock
Jun 13 2023	SELL Bona fide gift	-	25,000 Reduced 2.4%	1,014,794 Common Stock
Mar 21 2023	BUY Exercise of conversion of derivative security	$99,997 $3.22 p/Share	31,055 Added 2.9%	1,039,794 Common Stock
Feb 01 2023	SELL Open market or private sale	$1,038,000 $10.38 p/Share	100,000 Reduced 9.02%	1,008,739 Common Stock
Feb 01 2023	BUY Exercise of conversion of derivative security	$545,000 $5.45 p/Share	100,000 Added 8.27%	1,108,739 Common Stock
Dec 29 2022	SELL Bona fide gift	-	10,000 Reduced 0.98%	1,008,739 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	127,500 Added 11.16%	1,015,230 Common Stock
Dec 15 2022	SELL Open market or private sale	$153,690 $10.9 p/Share	14,100 Reduced 1.56%	887,730 Common Stock
Dec 02 2022	SELL Open market or private sale	$1,057,996 $12.8 p/Share	82,656 Reduced 8.4%	901,830 Common Stock
Dec 02 2022	BUY Exercise of conversion of derivative security	$117,371 $1.42 p/Share	82,656 Added 7.75%	984,486 Common Stock
Dec 01 2022	SELL Open market or private sale	$2,793,921 $13.0 p/Share	214,917 Reduced 19.24%	901,830 Common Stock
Dec 01 2022	BUY Exercise of conversion of derivative security	$305,182 $1.42 p/Share	214,917 Added 16.14%	1,116,747 Common Stock
Jan 11 2022	SELL Open market or private sale	$2,767,360 $15.04 p/Share	184,000 Reduced 16.95%	901,602 Common Stock
Jan 11 2022	BUY Exercise of conversion of derivative security	$870,320 $4.73 p/Share	184,000 Added 14.49%	1,085,602 Common Stock
Dec 14 2021	BUY Grant, award, or other acquisition	-	123,000 Added 12.0%	901,602 Common Stock
Sep 01 2021	SELL Bona fide gift	-	10,000 Reduced 1.27%	778,602 Common Stock
Dec 15 2020	SELL Open market or private sale	$1,117,193 $8.32 p/Share	134,278 Reduced 14.62%	784,086 Common Stock

Also insider at

BLCM

BELLICUM PHARMACEUTICALS, INC Healthcare

Director

JPS

Jon P Stonehouse

President & CEO

Houston, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BCRX shares.

Notify only if

Value

Insider Trading

Get notified when an Biocryst Pharmaceuticals Inc insider buys or sells BCRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOCRYST PHARMACEUTICALS INC

Track Activities on BCRX

Account